Literature DB >> 2138932

Expression of interleukin-2 receptor on blood lymphocytes stimulated with allogeneic lymphocytes or autologous tumor cells. The mixed lymphocyte culture of allo-sensitized individuals and the auto-tumor stimulation show similar kinetics of activation.

G Stuber1, F Vánky, E Pócsik, M Benczúr, E Klein.   

Abstract

The kinetics of interleukin-2 receptor (IL-2R) expression and the [3H]dT incorporation of blood lymphocytes after the first and the second stimulation with allogeneic leukocytes (primary and secondary MLC) or with the autologous tumor cells (primary and secondary MLTC) were compared. The expression of IL-2R paralleled the induction of DNA synthesis. The proportion of IL-2R+ cells of the unprimed donors peaked earlier in the secondary MLC as compared to the primary MLC (on days 3 and 5 respectively). In MLC of alloimmunized healthy individuals and in the MLTC of cancer patients the highest proportions of IL-2R+ cells were detected between days 2 and 3 after both the first and second stimulations. Thus the first in vitro stimulation in the MLTC showed similar kinetics to those of the secondary MLC of unprimed individuals and to the primary MLC response of the allo-immunized individuals. The findings in the MLTC substantiate the hypothesis that cancer patients can be sensitized to their own tumors. The kinetics of the appearance of the IL-2R together with the characteristics of the IL-2-propagated cultures provide useful information for the strategy of expansion of auto-tumor reactive lymphocyte populations.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2138932     DOI: 10.1007/bf01742369

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  17 in total

1.  Proliferation of T lymphocytes in response to interleukin 2 varies with their state of activation.

Authors:  J D Ashwell; R J Robb; T R Malek
Journal:  J Immunol       Date:  1986-10-15       Impact factor: 5.422

Review 2.  Immunotherapy of cancer using interleukin 2: current status and future prospects.

Authors:  S A Rosenberg
Journal:  Immunol Today       Date:  1988-02

3.  The human primary immune response to keyhole limpet haemocyanin: interrelationships of delayed hypersensitivity, antibody response and in vitro blast transformation.

Authors:  J E Curtis; E M Hersh; J E Harris; C McBride; E J Freireich
Journal:  Clin Exp Immunol       Date:  1970-04       Impact factor: 4.330

4.  The immunologic significance of antigen induced lymphocyte transformation in vitro.

Authors:  J A Mills
Journal:  J Immunol       Date:  1966-08       Impact factor: 5.422

5.  A monoclonal antibody that appears to recognize the receptor for human T-cell growth factor; partial characterization of the receptor.

Authors:  W J Leonard; J M Depper; T Uchiyama; K A Smith; T A Waldmann; W C Greene
Journal:  Nature       Date:  1982-11-18       Impact factor: 49.962

6.  The IL-2 receptor beta chain (p70): role in mediating signals for LAK, NK, and proliferative activities.

Authors:  J P Siegel; M Sharon; P L Smith; W J Leonard
Journal:  Science       Date:  1987-10-02       Impact factor: 47.728

7.  Lymphocyte cytotoxicity against autologous tumour biopsy cells in humans.

Authors:  B M Vose; F Vanky; E Klein
Journal:  Int J Cancer       Date:  1977-10-15       Impact factor: 7.396

Review 8.  Membrane structures involved in auto-tumor recognition.

Authors:  F Vánky
Journal:  Biochim Biophys Acta       Date:  1986-12-17

9.  Expression of receptors for interleukin 2: Role in the commitment of T lymphocytes to proliferate.

Authors:  S Lipkowitz; W C Greene; A L Rubin; A Novogrodsky; K H Stenzel
Journal:  J Immunol       Date:  1984-01       Impact factor: 5.422

10.  Lysis of autologous tumor cells by blood lymphocytes tested at the time of surgery. Correlation with the postsurgical clinical course.

Authors:  F Vánky; E Klein; J Willems; K Böök; T Ivert; A Péterffy; U Nilsonne; A Kreicbergs; T Aparisi
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.